Introduction
Belgium can be an important entry point for pharmaceutical companies seeking access to the European market. However, entering the Belgian market involves more than obtaining marketing authorisation. Sponsors must select an appropriate regulatory pathway, prepare a compliant dossier, address national language requirements and establish arrangements for ongoing product compliance.
Understanding Belgium drug registration requirements early helps companies identify regulatory gaps before submission, coordinate European and national activities, and prepare for the practical demands of launching a medicine. The right approach depends on the product, its existing authorisation status and whether Belgium is the only target market or part of a broader European strategy.
For sponsors planning Belgium pharmaceutical market entry, the priority should be to align regulatory planning with product eligibility, submission readiness and launch requirements from the beginning.
Understanding Belgium's Pharmaceutical Regulatory Framework
Belgium operates within the European Union (EU) pharmaceutical framework. Its national medicines authority is the Federal Agency for Medicines and Health Products (FAMHP), also known by the French abbreviation AFMPS and the Dutch abbreviation FAGG. FAMHP oversees medicines for human use and performs national regulatory functions, including the management of marketing authorisation application under applicable procedures, assessment of product documentation, and oversight of medicine quality and safety. It also manages relevant post-authorisation activities, including variations and renewals.
The European Medicines Agency (EMA) coordinates scientific assessment for medicines submitted through the centralised procedure. Following a positive EMA scientific opinion, the European Commission grants the marketing authorisation, which is valid throughout the EU.
A centralised authorisation generally covers Belgium without a separate national marketing authorisation application. For medicines authorised through national, decentralised or mutual recognition procedures, the scope of the authorisation depends on the countries covered by the relevant procedure. Sponsors should establish which authority and procedure apply before committing resources to a submission. The official FAMHP marketing authorisation guidance provides information on the available procedures and related requirements.
Belgium Drug Registration Requirements for Pharmaceutical Sponsors
The main FAMHP requirements depend on the medicine, its legal classification, the selected procedure and the evidence already available. In general, an application must demonstrate that the medicine meets the applicable standards for quality, safety and efficacy.
Sponsors should assess the following areas before submission:
- Applicant and authorisation-holder eligibility: Confirm that the proposed applicant and marketing authorisation holder (MAH) meet the applicable legal requirements, including the relevant establishment requirements.
- Quality and manufacturing compliance: Prepare information on the active substance, finished product, manufacturing process, specifications, controls, stability and relevant GMP compliance.
- Non-clinical and clinical evidence: Establish that the supporting evidence is appropriate for the product and application type. Generic, hybrid and other abridged applications may follow different evidence requirements from applications for new active substances.
- Product information: Prepare the Summary of Product Characteristics (SmPC), package leaflet and labelling in accordance with the applicable EU and Belgian requirements.
- Pharmacovigilance arrangements: Ensure that the required pharmacovigilance system information, qualified personnel arrangements and risk management documentation are available where applicable.
- Electronic dossier compliance: Confirm the applicable submission format, technical validation requirements and administrative documentation. FAMHP requires electronic Common Technical Document (eCTD) submissions for human-medicine marketing authorisation applications.
A complete dossier is not simply a collection of documents. Its quality also depends on consistency across the clinical, non-clinical, quality and product-information sections. Differences between these components can lead to additional questions and avoidable rework.
Which Marketing Authorisation Pathway Applies in Belgium?
Belgium uses the main EU marketing authorisation procedures. The appropriate route depends on the medicine’s eligibility, its existing authorisation status and the markets the sponsor intends to enter.
- National procedure: This route may be appropriate when authorisation is sought in Belgium alone and the medicine is eligible for a national application. Sponsors should confirm the relevant national requirements and submission arrangements with FAMHP.
- Decentralised procedure (DCP): This procedure is used when a medicine has not yet received a marketing authorisation in an EU Member State and the applicant seeks authorisation in several Member States at the same time. Belgium may participate as the reference or concerned Member State, depending on the procedure.
- Mutual recognition procedure (MRP): This procedure applies when a medicine already holds a national marketing authorisation in one EU Member State and the sponsor seeks recognition in additional Member States, including Belgium.
- Centralised procedure: This route results in one EU-wide marketing authorisation following EMA scientific assessment and a European Commission decision. It is mandatory for certain categories of medicines and available for other eligible products under the applicable rules.
These procedures are not interchangeable options for every medicine. Before selecting a route, sponsors should confirm the product’s classification, eligibility, existing authorisations and intended markets. A pathway assessment at this stage can prevent delays caused by pursuing an unsuitable procedure or preparing documentation for the wrong submission route.
Step-by-Step Process for Entering the Belgian Pharmaceutical Market
A structured approach to drug registration in Belgium helps sponsors move from regulatory planning to an application that is ready for submission and assessment. The Belgium drug approval process depends on the medicine’s eligibility, the applicable marketing authorisation procedure and the scope of the intended launch.
- Define the application scope. Confirm the medicine’s classification, intended indication, development or authorisation status, and whether the application covers Belgium alone or multiple EU markets.
- Select the appropriate authorisation procedure. Determine whether the national, decentralised, mutual recognition or centralised procedure applies. Confirm the product’s eligibility and identify the relevant authorities.
- Assess dossier readiness. Review the available quality, non-clinical, clinical, administrative and product-information documentation against the requirements of the selected procedure. Identify missing evidence and inconsistencies before submission.
- Compile and validate the submission. Prepare the applicable Common Technical Document (CTD) modules, complete the required administrative forms and verify that the electronic submission meets current technical and procedural requirements. Check the latest FAMHP instructions, including applicable application-form requirements.
- Submit the application and manage assessment. Follow the relevant submission process, address validation issues and coordinate clear, evidence-based responses to regulatory questions within the applicable timelines.
- Implement authorisation requirements. Once authorisation is granted, ensure that the approved product information, packaging and other applicable national requirements are implemented correctly.
- Coordinate launch activities. Align regulatory completion with supply readiness, pharmacovigilance arrangements and any separate Belgian pricing or reimbursement activities.
The overall timeline varies according to the authorisation procedure, application type, dossier quality, assessment questions and any additional national activities. Sponsors should plan against the applicable procedural timetable rather than assume that every medicine follows the same approval schedule.
Documents and Information Sponsors Should Prepare
The documentation required for a Belgian marketing authorisation depends on the product and procedure. Sponsors should establish a product-specific checklist rather than rely on a single list for all applications.
Upcoming FAMHP application form update: FAMHP has announced that the revised Marketing Authorisation Application Form, version 1.28.0.0, may be used from 1 September 2026 for national, mutual recognition and decentralised applications. Its use becomes mandatory for new submissions from 1 January 2027. Sponsors preparing Belgian applications should check the latest FAMHP instructions and ensure that the correct form version is used for their submission date.
The dossier may include:
- Administrative forms and applicant information.
- Quality documentation covering the active substance, finished product, manufacturing process, specifications and stability.
- Non-clinical and clinical study reports, where required.
- The proposed SmPC, package leaflet and labelling.
- Pharmacovigilance system information and a risk management plan, where applicable.
- Supporting certificates, declarations and other documents required for the specific application.
- Technical materials and validation checks needed for the applicable electronic submission format.
The evidence package for a generic or other abridged application may differ substantially from that required for a new active substance. Sponsors should confirm the relevant legal basis and dossier requirements before compiling the submission.
Language planning also deserves early attention. FAMHP’s instructions distinguish between national and European procedures, and the applicable language arrangements depend on the procedure and product. Sponsors should confirm the required language versions for the dossier, SmPC, package leaflet and packaging rather than assume that the same language rule applies to every submission.
Belgium’s national languages are Dutch, French and German. The language area and applicable product-information requirements must be checked for the specific application and intended market. Translation quality, consistency between language versions and alignment with the approved product information should be managed as part of dossier preparation—not left until the end of the process.
Post-Authorisation Requirements in Belgium
Marketing authorisation is the beginning of the product’s regulated lifecycle, not the end of the sponsor’s responsibilities.
Depending on the product and authorisation route, the MAH may need to manage:
- Pharmacovigilance: Maintain the applicable safety-monitoring system, process and report adverse reactions within the relevant timelines, and comply with applicable risk-management obligations.
- Variations: Submit and implement changes to the authorised medicine in accordance with the applicable variation procedure. Changes may involve manufacturing, quality specifications, product information or other authorised particulars.
- Renewals: Track the validity and renewal requirements of the authorisation. For human medicines, an initial marketing authorisation is generally valid for five years; following renewal, it normally becomes valid for an unlimited period unless a further time-limited renewal is justified on pharmacovigilance grounds.
- Product information maintenance: Keep the SmPC, package leaflet and labelling aligned with approved changes and applicable safety updates.
- Manufacturing and distribution compliance: Maintain appropriate quality and distribution arrangements and ensure that relevant changes are assessed for regulatory impact.
- Regulatory intelligence: Monitor relevant Belgian and EU requirements that may affect the medicine’s authorisation, safety profile or continued supply.
The exact obligations depend on the product and its authorisation. Sponsors should maintain a lifecycle plan that identifies responsible teams, reporting timelines, submission dependencies and implementation activities.
FAMHP provides information on variations and other post-authorisation procedures.
Common Regulatory Challenges for Sponsors Entering Belgium
Several practical issues can complicate Belgium drug registration requirements and delay a planned launch.
- Choosing an unsuitable procedure: Selecting a route without confirming product eligibility or the status of existing EU authorisations can lead to avoidable replanning.
- Dossier inconsistencies: Differences between quality information, clinical evidence and proposed product information can trigger additional regulatory questions.
- Incomplete electronic submissions: Missing documents, administrative errors or technical validation issues can delay the start or progression of assessment.
- Late language planning: Delayed translation, inconsistent terminology or incorrect assumptions about the required language versions can create additional work during submission or national implementation.
- Unclear responsibility across markets: Sponsors using a European procedure may need to coordinate multiple authorities, internal teams and local partners. Poor coordination can delay responses and implementation.
- Insufficient post-authorisation planning: Overlooking pharmacovigilance, variations, renewals or product-information updates can create compliance risks after approval.
- Confusing authorisation with reimbursement: A marketing authorisation does not automatically secure reimbursement or guarantee commercial uptake in Belgium.
These risks can often be reduced through early pathway assessment, a documented gap analysis, clear ownership of regulatory activities and a launch plan that covers both authorisation and post-authorisation responsibilities.
How Sponsors Can Prepare for Belgian Market Entry
Successful Belgium pharmaceutical market entry requires strategic decisions before the application is submitted. Beyond preparing the dossier, sponsors should establish the legal, organisational and operational arrangements needed to support the medicine throughout its lifecycle.
- Confirm the marketing authorisation-holder arrangements. Determine which entity will hold the marketing authorisation and verify that it meets the applicable establishment and eligibility requirements. Companies based outside the European Economic Area should assess the relevant requirements and local arrangements early.
- Assign clear responsibilities. Define ownership across regulatory affairs, quality, clinical, pharmacovigilance, supply and commercial teams. Establish who will coordinate regulatory communications, approve product information, manage safety obligations and implement post-authorisation changes.
- Plan resources and submission dependencies. Identify the expertise, translation support, documentation and technical publishing capabilities needed for the application. Agree on internal deadlines and dependencies so that outstanding inputs do not delay dossier completion or submission.
- Coordinate Belgium with the wider European strategy. Decide whether Belgium is an individual target market or part of a multi-country launch. Align the Belgian workstream with the chosen EU procedure, participating markets and shared dossier requirements while accounting for applicable national requirements.
- Prepare for obligations beyond approval. Establish processes for pharmacovigilance, variations, renewals, product-information maintenance and regulatory intelligence. Where relevant, plan separately for pricing, reimbursement, distribution and commercial launch activities.
Addressing these decisions early helps sponsors establish clear accountability, reduce avoidable coordination gaps and create a more realistic plan for entering Belgium and maintaining compliance after authorisation.
How Regulatory Affairs Consulting Can Support Market Entry in Belgium
Regulatory affairs support can be useful when sponsors need to assess product eligibility, coordinate submissions or manage Belgian requirements alongside activities in other markets.
DDReg provides regulatory affairs services in Belgium, including support for regulatory strategy services, new product authorisations, dossier preparation and publishing, regulatory gap analysis, CMC advisory, labelling services and post-approval lifecycle management. The appropriate scope depends on the product, the selected procedure and the sponsor’s internal capabilities.
For sponsors preparing a Belgian submission, support may include reviewing the proposed pathway, assessing dossier readiness, identifying documentation gaps, coordinating submission requirements and planning post-authorisation activities. Where Belgium is part of a broader EU strategy, regulatory planning can also help align the Belgian workstream with the wider submission programme.
Conclusion
Successful entry into Belgium depends on making the right regulatory decisions before submission and maintaining compliance after authorisation. Sponsors should confirm the applicable pathway, assess dossier readiness, plan for Belgian language requirements and establish clear responsibilities for pharmacovigilance and lifecycle management.
For companies pursuing a wider European launch, Belgium should be considered within the overall regulatory strategy rather than treated as an isolated filing. Early planning helps identify gaps, coordinate national and EU requirements and establish a more realistic path from submission to market readiness. With a structured approach and appropriate regulatory support, sponsors can manage the requirements more effectively and build a stronger foundation for sustainable access to the Belgian market.
Frequently Asked Questions
The requirements depend on the medicine, its legal basis and the selected marketing authorisation procedure. Applications generally require appropriate quality, safety and efficacy evidence, administrative documentation, product information and applicable pharmacovigilance materials. Human-medicine marketing authorisation applications must also meet the relevant electronic submission requirements.
FAMHP is Belgium's national medicines authority. It manages national regulatory responsibilities, including applicable marketing authorisation procedures, assessment of medicine documentation and post-authorisation activities. For centrally authorised medicines, EMA coordinates the scientific assessment, and the European Commission grants the EU-wide marketing authorisation.
A foreign company should confirm the medicine's eligibility, select the appropriate national or European procedure, assess dossier readiness and establish an eligible marketing authorisation-holder arrangement. It should also plan for applicable language requirements, pharmacovigilance, supply responsibilities and any separate pricing or reimbursement steps.
Depending on the product and its eligibility, the available routes include the national procedure, decentralised procedure, mutual recognition procedure and centralised procedure. These routes have different eligibility conditions and scopes, so the appropriate option should be confirmed before submission planning begins.
The application may include administrative forms, CTD quality documentation, non-clinical and clinical evidence where required, proposed product information, pharmacovigilance documentation and supporting certificates or declarations. The exact package depends on the product and procedure, and the applicable electronic submission requirements must also be met.
Yes. Sponsors must comply with the language requirements applicable to the product, authorisation procedure and intended Belgian market. Dutch, French and German are Belgium's national languages, but the specific language arrangements should be confirmed against current FAMHP guidance rather than assuming that every application follows the same rule.
Marketing authorisation holders must comply with the applicable EU and Belgian pharmacovigilance requirements. Depending on the medicine, these may include adverse-reaction reporting, safety monitoring, maintenance of pharmacovigilance-system documentation, risk management and submission of periodic safety reports where required.